Morphosy Phase News Today

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds despite setbacks.

Myelofibrosis is a type of blood cancer characterized by the buildup of scar tissue, called “fibrosis,” in the bone marrow. Physicians participating in…

EQS-News: MorphoSys AG / Key word: Forecast MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...

EQSAdhoc MorphoSys AG Key word Forecast Ad hoc MorphoSys AG Reports Preliminary 2023 Monjuvi US Net Product Sales and Gross Margin Provides 2024 Financial Guidance and Reduces Financial Liability 30J

MorphoSys AG / Key word(s): ForecastAd hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability30-Jan-2024 / 08:47 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014,...

EQS-News: MorphoSys AG / Key word(s): ForecastMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability 30.01.2024 / 08:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Mu...

EQS-Ad-hoc: MorphoSys AG / Key word: Forecast Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...

EQSAdhoc MorphoSys AG Key word Study results Ad hoc MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Po